Search | IOVS | ARVO Journals

View

Showing 1 – 19 of 19

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Low Dose, Subconjunctival Administration of VEGF Trap Inhibits Suture–Induced Corneal Neovascularization and Inflammation

Y. Liu; J. Cao; R.A. Renard; H. Song; D. Hylton; J.S. Rudge; N. Papadopoulos; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1626. doi:

ARVO Annual Meeting Abstract May 2006

Intravitreal Administration of VEGF Trap Suppresses Vascular Leak in the Retinas of Diabetic Rats

J. Cao; H. Song; Y. Liu; R.A. Renard; I.B. Lobov; N. Papadopoulos; J.S. Rudge; D. Hylton; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1745. doi:

ARVO Annual Meeting Abstract May 2006

Intravitreal Administration of VEGF Trap Inhibits Pathological Retinal Neovascularization in a Mouse Model of Oxygen Induced Retinopathy

R.A. Renard; I.B. Lobov; Y. Liu; J. Cao; K.D. Anderson; N.J. Papadopoulos; J.S. Rudge; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):1750. doi:

ARVO Annual Meeting Abstract May 2006

Histologic Evaluation of Laser–Induced Choroidal Neovascularization (CNV) in Primates Receiving Intravitreal Injections of VEGF Trap: Correlation With Fluorescein Angiography

S.J. Wiegand; R. Dubielzig; E.P. Zimmer; T.M. Nork; P.E. Miller; B.J. Christian; J. Cao; J. Cedarbaum; G.D. Yancopoulos; E. Furfine

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2188. doi:

ARVO Annual Meeting Abstract May 2006

Deletion of a Single Dll4 Allele Alters Retinal Vascular Development in Mice

I.B. Lobov; R.A. Renard; N. Papadopoulos; G. Thurston; N.W. Gale; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):3877. doi:

ARVO Annual Meeting Abstract May 2005

Systemic Administration of VEGF Trap Suppresses Vascular Leak and Leukostasis in the Retinas of Diabetic Rats

J. Cao; H. Song; R.A. Renard; Y. Liu; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):446. doi:

ARVO Annual Meeting Abstract May 2005

VEGF Trap Both Prevents Experimental Choroidal Neovascularization and Causes Regression of Established Lesions in Non–Human Primates

S.J. Wiegand; E. Zimmer; T.M. Nork; P.E. Miller; B.J. Christian; J.M. Miller; J. Cao; J. Cedarbaum; G.D. Yancopoulos; E. Furfine

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):1411. doi:

ARVO Annual Meeting Abstract May 2005

Genetic Deletion of Pigment Epithelium–Derived Factor (PEDF) Does Not Alter the Development, or Subsequent Regression, of Pathological Neovascularization in a Mouse Model of Oxygen–Induced Retinopathy

R.A. Renard; J. Cao; Y. Liu; H. Song; K.D. Anderson; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):3258. doi:

ARVO Annual Meeting Abstract May 2005

Low Dose or Transient Administration of VEGF Trap Suppresses Corneal Neovascularization and Inflammation

H. Song; J. Cao; Y. Liu; R.A. Renard; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):4497. doi:

ARVO Annual Meeting Abstract May 2005

Inhibition of Angiogenesis and Lymphangiogenesis After High–Risk Keratoplasty by Neutralizing VEGF–A Improves Corneal Graft Survival

B.O. Bachmann; E. Lütjen–Drecoll; S.J. Wiegand; J.W. Streilein; F.E. Kruse; C. Cursiefen

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):4743. doi:

ARVO Annual Meeting Abstract May 2005

Complete Inhibition of Neovascularization by VEGF Trap in a Matrigel CNV Model

L. Zhao; Y. Liu; Y. Li; Y. Song; A.M. Laties; J.S. Rudge; S.J. Wiegand; R. Wen

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):5300. doi:

ARVO Annual Meeting Abstract May 2005

VEGF Trap Induces Significant Regression of Existing Choroidal Neovascularization (CNV)

R. Wen; L. Zhao; Y. Liu; Y. Li; Y. Song; J.S. Rudge; A.M. Laties; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):5307. doi:

ARVO Annual Meeting Abstract May 2004

Genetic modulation of pigment epithelium–derived factor (PEDF) expression does not alter normal or pathological angiogenesis in the eye, or tumor growth.

S.J. Wiegand; H. Song; R. Renard; P. Kraus; N.W. Gale; I. Noguera; Y. Qian; J. Holash; G.D. Yancopoulos; J. Cao

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):1884. doi:

ARVO Annual Meeting Abstract May 2004

Subconjunctival Administration of VEGF Trap Suppresses Corneal Neovascularization

J. Cao; H. Song; R. Renard; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):2346. doi:

ARVO Annual Meeting Abstract May 2003

Eye Phenotype of Pigment Epithelium-Derived Factor Knockout Mice

R.A. Renard; J. Cao; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):2888. doi:

ARVO Annual Meeting Abstract May 2003

The Expression of Angiogenic Factors and Their Receptors During Retinal Neovascularization: Effects of VEGF Trap Administration

Q. Wang; F. Martin; A. Lalla; L. Malinova; M.W. Sleeman; J.S. Rudge; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):2902. doi:

ARVO Annual Meeting Abstract May 2003

VEGF-TRAPR1R2 Suppresses Choroidal Neovascularization(CNV) and VEGF-Induced Breakdown of the Blood-Retinal Barrier(BRB)

Y. Saishin; Y. Saishin; K. Takahashi; R. Lima Silva; D. Hylton; J.S. Rudge; S.J. Wiegand; P.A. Campochiaro

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):3920. doi:

ARVO Annual Meeting Abstract May 2003

Inhibition of IL-1 Blocks Corneal Inflammation and Neovascularization

J. Cao; R. Renard; H. Song; E. Ioffe; V. Mosher; J.S. Rudge; E.M. Koehler-Stec; G.D. Yancopoulos; S.J. Wiegand

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):823. doi:

ARVO Annual Meeting Abstract May 2003

Long-lasting Inhibition of Corneal Neovascularization following Systemic Administration of the VEGF Trap

S.J. Wiegand; J. Cao; R. Renard; J.S. Rudge; G.D. Yancopoulos

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):829. doi:

Advertisement